Comparative Pharmacology
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORAZEPAM PRESERVATIVE FREE versus PAXIPAM.
LORAZEPAM PRESERVATIVE FREE vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances GABA-A receptor activity, increasing chloride ion conductance and producing sedative, anxiolytic, anticonvulsant, and muscle relaxant effects.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
0.5-2 mg orally every 6-8 hours as needed; maximum 4 mg/day. IV: 0.044 mg/kg (max 4 mg) every 6-8 hours for acute anxiety or sedation.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12–14 hours (range 10–20 h). Clinically, no active metabolites; accumulation minimal at standard dosing intervals.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal: ~88% as glucuronide conjugates; <1% unchanged. Fecal: ~7%. Biliary: minor.
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine